NMN and Heart Ageing: What a New Study Found

A newly published study has added another interesting data point to the growing body of NMN research.

In this 2026 preclinical study, researchers investigated whether nicotinamide mononucleotide (NMN) could help reduce signs of cardiac ageing and heart tissue damage in older mice fed a high-fat diet. You can view the published study HERE. The authors reported that NMN helped alleviate high-fat-diet-induced myocardial damage in ageing mice, with effects linked to the Sirt3/PINK1/Parkin signalling pathway and improved autophagy-lysosomal function.

Importantly, this was not a human clinical trial. It was a mouse study, so while the findings are promising, they should be viewed as early-stage research rather than proof of the same effect in people.

What did the new NMN study investigate?

The study looked at whether NMN could help protect the ageing heart under conditions of metabolic stress.

Researchers used an ageing mouse model and examined the effects of a high-fat diet, which is often used in preclinical research to study metabolic dysfunction, inflammation, and tissue stress. They then assessed whether NMN could reduce heart tissue damage and support key cellular pathways involved in maintaining healthy cardiac function.

What did the researchers find?

According to the published abstract and journal listing, the researchers found that NMN:

• Reduced high-fat-diet-induced myocardial damage in ageing mice
• Supported the Sirt3/PINK1/Parkin signalling pathway
• Helped enhance autophagy-lysosomal function, a cellular “clean-up” system involved in removing damaged cellular components
• Appeared to support mitochondrial quality control, which is highly relevant in ageing research

In simple terms, the study suggests NMN may help the heart cope better with age-related and diet-related stress in this particular preclinical model.

Why is this relevant?

One reason NMN continues to attract attention is its role as a precursor to NAD+.

NAD+ is a molecule involved in cellular energy production, mitochondrial function, and repair processes. NAD+ levels tend to decline with age, which is one reason NAD+ precursors such as NMN are widely studied in healthy ageing research. A 2022 review noted that NMN has shown encouraging results in many in vivo (animal) studies, while also emphasising that more robust human clinical evidence is still needed.

How does this fit with broader NMN cardiovascular research?

This new study is not the first to explore NMN in a cardiovascular context.

Other recent preclinical work has reported that NMN may help protect against high-fat-diet-induced atherosclerosis in mice, while broader reviews have discussed the growing interest in NAD+ metabolism and cardiovascular ageing. However, much of this evidence remains preclinical, and human outcome data is still more limited than many supplement headlines suggest.

That is why we think the most sensible approach is to follow the research with interest, while keeping expectations grounded.

Important note: this was a mouse study, not a human trial

This is the key takeaway.

This study is interesting and relevant, but it should not be interpreted as proof that NMN will produce the same heart-related benefits in humans.

At MyVitality, we share new research when we think it is useful and worth knowing about, but we also believe it is important to be clear about the difference between:

• preclinical findings
• mechanistic evidence
• and confirmed human clinical outcomes

Our view at MyVitality

We think this is another worthwhile study to keep an eye on.

It adds to the broader scientific interest in NMN, especially around ageing, metabolism, mitochondrial function, and cellular resilience. But like many NMN studies, it is best viewed as promising early-stage research, not a definitive clinical result.

If you are interested in the science behind NMN, this is another example of why NMN remains one of the most closely followed nutrients in the healthy ageing space.

You can view our NZ-made NMN here: https://myvitality.co.nz/product/nmn-60-capsules/

FAQ

Does NMN support heart health?

Current interest in NMN and heart health comes mainly from preclinical research. This new study suggests NMN may help reduce signs of cardiac damage in ageing mice under metabolic stress, but it does not prove the same effect in humans. More human research is needed.

Was this new NMN study done in humans?

No. This was a preclinical mouse study, not a human clinical trial. That means the findings are scientifically interesting, but they should be interpreted as early-stage evidence rather than a confirmed human health outcome.

Why is NMN studied in healthy ageing research?

NMN is a precursor to NAD+, a molecule involved in cellular energy metabolism and repair processes that tend to decline with age. That is one reason NMN continues to be studied in a range of ageing-related areas.